

Dr. Balogh Balázs
KÖZLEMÉNYEK LISTÁJA
2003-2017

1. Anwair M.A.S., Károlyházy L., Szabó D., **Balogh B.**, Kövesdi I., Harmat V., Krenyác J., Gellért Á., Takács-Novák K., Mátyus P.:
Lipophilicity of aminopyridazinone regioisomers.
J. Agric. Food Chem., **51**, 5262-5270 (2003). DOI:10.1021/jf0343938
IF 2.102
2. Keglevich Gy., Kégl T., Chuluunbaatar T., Dajka B., Mátyus P., **Balogh B.**, Kollár L.:
Hydroformylation of styrene in the presence of rhodium-2,4,6-trialkylphenyl-phosphole
in situ catalytic systems.
J. Mol. Catal. A: Chem., **200**, 131-136 (2003). DOI:10.1016/S1381-1169(03)00046-3
IF 2.264
3. Bágyi I., **Balogh B.**, Czajlik A., Éliás O., Gáspári Z., Gergely V., Hudáky I., Hudáky P.,
Kalászi A., Károlyházy L., Keserű K., Kiss R., Krajsovsky G., Láng B., Nagy T.,
Rác Á., Szentesi A., Tábi T., Tapolcsányi P., Vaik J., Koo J.C.P., Chass G.A.,
Farkas Ö., Perczel A., Mátyus P.:
Generation and analysis of the conformational potential energy surfaces of
N-acetyl-*N*-methyl-L-alanine-*N*'-methylamide. An exploratory ab initio study.
J. Mol. Struct. (Theochem), **625**, 121-136 (2003). DOI:10.1016/S0166-1280(03)00009-5
IF 1.027
4. Borosy A.P., **Balogh B.**, Mátyus P.:
Alignment-free descriptors for quantitative structure-rate constant relationships of
[4+2]cycloadditions.
J. Mol. Struct. (Theochem), **729**, 169-176 (2005). DOI:10.1016/j.theochem.2005.01.054
IF 1.045
5. **Balogh B.**, Hetényi Cs., Keserű Gy.M., Mátyus P.:
Structure-based calculation of binding affinities of α_{2A} -adrenoceptor agonists.
ChemMedChem, **2**, 801-805 (2007). DOI:10.1002/cmdc.200600251
IF 2.825
6. Jójárt B., **Balogh B.**, Márki A.:
Modeling the human oxytocin receptor for drug discovery efforts.
Expert Opin. Drug Discovery, **2**, 1579-1590 (2007). DOI:10.1517/17460441.2.12.1579
IF 1.354 (2009)
7. **Balogh B.**, Jójárt B., Wágner Zs., Kovács P., Gyires K., Zádori Z., Falkay Gy.,
Márki Á., Viskolcz B., Mátyus P.:
3D QSAR models for α_{2a} -adrenoceptor agonists.
Neurochem. Int., **51**, 268-276 (2007). DOI:10.1016/j.neuint.2007.05.021
IF 2.975

8. Daruházi Á.E., Szente L., **Balogh B.**, Mátyus P., Béni Sz., Takács M., Gergely A., Horváth P., Szőke É., Lemberkovichs É.:
Utility of cyclodextrins in the formulation of genistein Part 1. Preparation and physicochemical properties of genistein complexes with native cyclodextrins.
J. Pharm. Biomed. Anal. **48**, 636-640 (2008). DOI:10.1016/j.jpba.2008.06.007
IF 2.629
9. **Balogh B.**, Szilágyi A., Gyires K., Bylund D.B., Mátyus P.:
Molecular modelling of subtypes (α_{2A} , α_{2B} and α_{2C}) of α_2 adrenoceptors: A comparative study.
Neurochem. Int., **55**, 355-361(2009). DOI:10.1016/j.neuint.2009.05.004
IF 3.541
10. Mercader J., Iffiú-Soltész Zs., Brenachot X., Földi Á., Dunkel P., **Balogh B.**, Attané C., Valet P., Mátyus P., Carpéné C.:
SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders.
Future Med. Chem., **2**, 1735-1749 (2010). DOI:10.4155/fmc.10.260
IF 1.424
11. Dunkel P., **Balogh B.**, Meleddu R., Maccioni E., Gyires K., Mátyus P.:
Semicarbazide sensitive amine oxidase/vascular adhesion protein-1: A patent survey.
Expert Opin. Ther. Patents, **21**, 1453-1471 (2011). DOI:10.1517/13543776.2011.594040
IF 3.571
12. Arany Á., Bolgár B., **Balogh B.**, Antal P., Mátyus P.:
Multi-aspect candidates for repositioning: Data fusion methods using heterogeneous information sources.
Curr. Med. Chem., **20**, 95-107 (2013). DOI:10.2174/0929867311302010010
IF 3.715
13. Bolgár B., Arany Á., Temesi G., **Balogh B.**, Antal P., Mátyus P.:
Drug repositioning for treatment of movement disorders: From serendipity to rational discovery strategies.
Curr. Top. Med. Chem., **13**, 2337-2367 (2013). DOI:10.2174/15680266113136660164
IF 3.453
14. Tóth L., Fu Y., Zhang H.Y., Mándi A., Kövér K.E., Illyés T.Z., Kiss-Szikszai A., **Balogh B.**, Kurtán T., Antus S., Mátyus P.:
Preparation of neuroprotective condensed 1,4-benzoxazepines by regio- and diastereoselective domino knoevenagel-[1,5]-hydride shift-cyclization reaction.
Beilstein J. Org. Chem., **10**, 2594-2602 (2014). DOI:10.3762/bjoc.10.272
IF 2.757

16. Parrino B., Carbone A., Ciancimino C., Spano V., Montalbano A., Barraja P., Cirrincione G., Diana P., Sissi C., Palumbo M., Pinato O., Pennati M., Beretta G., Folini M., Mátyus P., **Balogh B.**, Zaffaroni N.:
Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: In vitro antiproliferative activity and molecular mechanism(s) of action.
Eur. J. Med. Chem., **94**, 149-162 (2015). DOI:10.1016/j.ejmech.2015.03.005
IF 3.902

17. Huleatt P.B., Khoo M.L., Chua Y.Y., Tan T.W., Liew R.S., **Balogh B.**, Deme R., Gölöncsér F., Magyar K., Sheela D.P., Ho H.K., Sperlág B., Mátyus P., Chai C.L.L.:
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
J. Med. Chem., **58**, 1400-1419 (2015). DOI:10.1021/jm501722s
IF 5.589

18. **Balogh B.**, Pázmány T., Mátyus P.:
Analysis of Edg-Like LPA receptor-ligand interactions.
Curr. Pharm. Des. **21**, 3533-3547 (2015). DOI:10.2174/1381612821666150216120500
IF 3.052

19. Carpéné C., Hasnaoui M., **Balogh B.**, Mátyus P., Fernandez-Quintela A., Rodriguez V., Portillo M. P., Mercader J.:
Dietary phenolic compounds interfere with the fate of hydrogen peroxide in human adipose tissue but do not directly inhibit primary amine oxidase activity.
Oxid. Med. Cell. Longevity ID 2427618 (2016). DOI:10.1155/2016/2427618
IF 4.492

20. Les Parellada F., Deleruyelle S., Cassagnes L. E., Nepveu F., Boutin J. A., **Balogh B.**, Arbones-Mainar J. M., Biron S., Marceau P., Richard D., Nepveu F., Mauriège P., Carpéné C.:
Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties.
Chem.-Biol. Interact. **258**, 115-125, (2016). DOI:10.1016/j.cbi.2016.07.014
IF 2.618

21. **Balogh B.**, Carbone A., Spano V., Montalbano, A., Barraja P., Cascioferro S., Diana P., Parrino B.:
Investigation of Isoindolo[2,1-a]quinoxaline-6-imines as topoisomerase I inhibitors with molecular modeling methods.
Curr. Comp.-Aided Drug Des. **13**, 208-221 (2017).
DOI:10.2174/1573409913666170124100334
IF 0.77

SZABADALOM

Mátyus P., Németh J., Magyar K., Somogyi A., Dunkel P., Somfai G.M., **Balogh B.**, Túros Gy.:

Use of dihydralazine for the treatment of diseases related to elevated semicarbazide-sensitive amine oxidase (SSAO) activity.

PCT Int. Appl. (2010), WO 2010015870 A1 20100211